Stock comparison
United Therapeutics
UTHR$24.13BHealthcare Market cap, Sector
Zoetis
ZTS$34.09BHealthcare Market cap, Sector
Overall winner
United Therapeutics
UTHR 52 ZTS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
UTHR5wins
2winsZTS
71B
C64
76B
B70
76B
C61
62C
F42
46D
F43
64C
C69
64C
B73
Side-by-side metrics
| Metric | UTHR | ZTS |
|---|---|---|
| Market cap | $24.13B | $34.09B Winner |
| P/E (TTM) | 19.2x | 11.9x Winner |
| EV/EBIT | 15.2x | 10.8x Winner |
| ROIC (TTM) | 18.81% | 21.79% Winner |
| Gross margin | Winner: 86.58% | 70.75% |
| Net margin | Winner: 40.61% | 27.79% |
| Revenue CAGR 5y | Winner: 17.22% | 5.04% |
| EPS CAGR 5y | Winner: 29.84% | 8.88% |
| Debt / Equity | Winner: - | 0.1x |
| Dividend yield | 0.0% | 2.77% Winner |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
UTHR leads on
- Debt / Equity-vs 0.1x+100%
- Revenue CAGR 5y17.22%vs 5.04%+71%
- EPS CAGR 5y29.84%vs 8.88%+70%
- Net margin40.61%vs 27.79%+32%
ZTS leads on
- Dividend yield2.77%vs 0.0%+100%
- P/E (TTM)11.9xvs 19.2x+38%
- Market cap$34.09Bvs $24.13B+29%
- EV/EBIT10.8xvs 15.2x+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.